Radiopeptide Therapy of Brain Tumors
The following chapter summarizes the results of the phase I and II studies that have been published dealing with radiopeptide therapy in brain tumors. To date, three radiopeptides conjugated with a chelator for radiolabeling with radiometals or labeled directly with 131I have been used in patients. Radiopeptide therapy for brain tumors has to be regarded as experimental. So far, the largest number of patients has been treated with substance P radiolabeled with 90Y, 177Lu, or 213Bi. Besides substance P, the somatostatin analog DOTATOC and the synthetic chlorotoxin TM-601 have been used for this therapy strategy.
KeywordsMalignant Glioma Resection Cavity Triacetic Acid Effective Dose Range Radiopeptide Therapy
- Beutler D, Avoledo P, Reubi JC et al (2005) Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 103:869–873PubMedCrossRefGoogle Scholar
- Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A (2010) Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: a pilot trial. Eur J Nucl Med Mol Imaging 37:1335–1344PubMedCrossRefGoogle Scholar
- Maecke HR (2005) Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop, pp 43–72Google Scholar
- Riva P, Arista A, Franceschi G et al (1995) Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55:5952s–5956sGoogle Scholar